BASEL, Switzerland,
Jan. 18 /PRNewswire/ - Neuro-Biotech
Corp. (PINKSHEET: MRES) (OTCQB: MRES) announces that it has
concluded a Business Development Agreement with Credo-TM, a Russian
company. The Agreement provides for an exclusive right to
distribute all Neuro-Biotech proprietary blood analysis kits and
NeuroCeuticals™ in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds
Credo-TM to a minimum yearly order of 500,000 test units for a term
of 10 years. Both parties have agreed on an initial price of
$55.00 USD per unit for its initial
launch. The pricing for subsequent years may be subject to
change.
Over the next three month, Credo-TM will be
selecting the laboratories mandated to undertake the tests
analysis. Neuro-Biotech will be overseeing the technician training
program for protocol analysis application.
ABOUT CREDO-TM
Credo-TM, a private entity, was created by a group of professors
and doctors from one of Russia's
oldest and largest human physiological health laboratory. The
company is based in the Techno Park area of Kazan City in the
Russian Federation. Over the past
several years Credo-TM has developed, with the help of government
grants, a solid distribution network of advanced and modern medical
products in countries such as Russia, Belarus, Ukraine and Kazakhstan. Close to 1200 medical centers and
hospitals are using the services of Credo-TM today. The Company's
initial effort was the distribution of diagnostic tests for
diabetes, pregnancy as well as tuberculosis (early stage). Over the
past 3 years, more than 300 employees have joined Credo-TM.
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions,
and that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or
obligation to update or revise forward-looking information, whether
as a result of new information, future events, or otherwise, could
cause the company's actual results to differ materially from those
indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 18 PR Newswire